Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1443-1452, February 2026.Abstract Objective This study provides real‐world evidence on the comparative effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) regarding the risk of incident dementia in adults with type 2 diabetes mellitus (T2DM).
Filippos Anagnostakis +4 more
wiley +1 more source
A polymorphism at IGF1 locus is associated with anemia [PDF]
, 2017 In vitro and in vivo studies suggest that IGF-1 has a role in erythropoiesis. There is evidence that the rs35767 C/T polymorphism near IGF1 is associated with plasma IGF-1 levels.
Andreozzi F +5 more
core +1 more source
Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. [PDF]
, 2018 OBJECTIVES: Describe and compare the risk of cardiovascular and non-cardiovascular mortality in patients whose antidiabetic therapy is modified to include pioglitazone compared with an alternative antidiabetic medication at the same stage of disease ...
Bahmanyar, Shahram +9 more
core +1 more source
Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 2, Page 210-223, February 2026.Optimal treatment for frontal fibrosing alopecia (FFA) remains contentious. An international expert panel agreed that highly/ultra‐potent topical steroids were the preferred first‐line topical therapy. Preferred systemic therapies were 5‐alpha reductase inhibitors, followed by hydroxychloroquine.
Nekma Meah +64 more
wiley +1 more source
PLoS ONE, 2012 BackgroundEvidence suggests that the PPARγ-agonist insulin sensitizer pioglitazone, may provide potential beneficial cardiovascular (CV) effects beyond its anti-hyperglycaemic function.
Valentina Spigoni +9 more
doaj +1 more source
The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. [PDF]
, 2018 Introduction:Cost of generic medications has risen more in the past few years than any other time in history. While medical insurance covers much of these costs, health care professionals can better provide medications that have the longest duration of ...
Cherukuri, Lavanya +2 more
core
Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis [PDF]
, 2015 MicroRNAs (miRNA) are a novel class of small noncoding single-stranded RNA molecules that regulate gene expression. There is increasing evidence of their importance in polycystic ovary syndrome (PCOS). The objective was to determine if miRNA-93 and miRNA-
Atkin, S. L. +3 more
core +1 more source
Effects of the peroxisome proliferator-activated receptor (PPAR)-γ agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals [PDF]
, 2018 Aims/hypothesis: Glitazones are powerful insulin sensitisers prescribed for the treatment of type 2 diabetes. Their use is, however, associated with fluid retention and an increased risk of congestive heart failure.
Burnier, M. +7 more
core
Exploring metabolic dysfunction in chronic kidney disease [PDF]
, 2012 Impaired kidney function and chronic kidney disease (CKD) leading to kidney failure and end-stage renal disease (ESRD) is a serious medical condition associated with increased morbidity, mortality, and in particular cardiovascular disease (CVD) risk ...
Slee, Adrian D.
core +2 more sources
Cellular Physiology and Biochemistry, 2016 Background/Aims: Pioglitazone is a type of peroxisome proliferator-activated receptor γ agonist and is capable of alleviating renal ischemia-reperfusion injury.
Li Sun +8 more
doaj +1 more source